news

CUPERTINO, Calif., Sept. 23, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival […]

Phase 2b study in subjects with Alcoholic Hepatitis to evaluate safety and efFIcacy of DUR-928 treatMent (AHFIRM) CUPERTINO, Calif., Sept. 22, 2020 /PRNewswire/ — DURECT Corporation (NASDAQ: DRRX) today announced the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe alcoholic hepatitis (AH) patients. AHFIRM is a randomized, double-blind, placebo-controlled, international, multi-center

CUPERTINO, Calif., Sept. 10, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the HC Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. HC Wainwright 22nd Annual Global Investment ConferenceDate                     Monday, September 14 Time:                    2:30-2:50 PM EDT (Fireside Chat with Ed Arce)Webcast:

CUPERTINO, Calif., Aug. 27, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress™ 2020 (EASL), taking place on August 27-29.  DUR-928 was well tolerated at all doses tested in 19 AH patients, including 12

CUPERTINO, Calif., Aug. 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ellie Merle of Cantor Fitzgerald, tomorrow, Thursday, August 27, 2020 at 11:00

CUPERTINO, Calif., Aug. 5, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT

Live Webcast of Earnings Call Today, August 3rd at 4:30 p.m. ET CUPERTINO, Calif., Aug. 3, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update. Total revenues were $25.8 million and net income was $14.3 million for the three months ended

CUPERTINO, Calif., July 28, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter 2020 financial results and host a conference call after the market close on Monday, August 3, 2020. Monday, August 3 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time Toll Free:                   877-407-0784 International:              201-689-8560 Conference ID:            13706541 Webcast:                      http://public.viavid.com/index.php?id=140595

– U.S. Food and Drug Administration (FDA) has authorized the investigational new drug (IND) application – Acute liver and kidney injury are risk factors for poor outcomes in COVID-19 patients – The risk of death from multi-organ failure is present in both patients with severe COVID-19 and those with severe Alcoholic Hepatitis (AH) – Promising Phase 2a clinical

CUPERTINO, Calif., June 29, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of